Cerity Partners
LGND icon

Cerity Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Cerity Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,531
Closed -$289K – 3333
2025
Q4 		$289K Buy
1,531
+79
+5% +$15.2K ﹤0.01% 2431
2025
Q3 		$257K Buy
+1,452
New +$216K ﹤0.01% 2385
2023
Q2 		– Sell
-205
Closed -$282K – 1824
2023
Q1 		$282K Buy
+205
New +$14.6K ﹤0.01% 1553
2018
Q4 		– Sell
-1,375
Closed -$236K – 537
2018
Q3 		$236K Buy
+1,375
New +$207K 0.02% 481

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Cerity Partners's LGND Position: Q1 2026 in Review

Cerity Partners sold out of Ligand Pharmaceuticals (LGND) in Q1 2026, closing a stake of 1,531 shares — an estimated $289K sold.

Cerity Partners first reported a position in LGND in Q3 2018 and held it in 4 quarters. The position peaked at $289K in Q4 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Cerity Partners reported no remaining Ligand Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Cerity Partners sold 1,531 Ligand Pharmaceuticals shares in Q1 2026, an estimated $289K.
  • Cerity Partners first reported a position in Ligand Pharmaceuticals in Q3 2018 and held it in 4 quarters.
  • Cerity Partners's Ligand Pharmaceuticals position peaked at $289K in Q4 2025.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.